HUS Technical sequencing at IHU Strasbourg: a world first in neoplastic diseases

HUS Technical sequencing at IHU Strasbourg: a world first in neoplastic diseases

At the IHU Strasbourg, Prof. Anne Olland and Prof. Pierre-Emmanuel Falcoz, of the Thoracic Surgery and Lung Transplant Department at the University Hospitals in Strasbourg, performed a ground-breaking technical sequencing on Thursday 26 October, benefiting from the institute’s specialty in image-guided minimally invasive robot-assisted surgery.

For the first time, the technical sequencing took place entirely on site, around the patient, who did not need to be transported from one examination to the next. This sequence enabled precise minimally invasive (robot-assisted surgery) and parenchymal sparing (controlled segmentectomy). This surgery offers greater precision and reliability in the early stages of neoplastic disease. The world-first sequencing also expands the IHU Strasbourg’s specialty domains, historically linked to digestive surgery.

This work was the fruit of close multidisciplinary collaboration with IBODEs, radio manipulators, intensive care anaesthetists, as well as interventional radiologists, management teams and industry representatives.


The offer of precise, reliable surgery on early-stage neoplastic disease: imaging as close as possible to the surgical procedure enables accurate 3-dimensional reconstruction on a CT scan performed on a patient who is already asleep and in the operating position at the time of surgery, with no positional shift and no lag in the evolution of the disease with a CT scan performed on the same day (compared with a CT scan usually performed lying down, with a lag of one to several days or even weeks in relation to the surgical procedure). The technical sequence takes place around the patient, who does not need to be transported from one examination to the next, enabling precise, minimally invasive, parenchymal-sparing surgery. This technical development remains linked to the HUS’s cross-disciplinary lung cancer research programs.

eCAP: Towards universal access to digestive disease diagnostics

eCAP: Towards universal access to digestive disease diagnostics

On 4 May 2022, a hybrid kick-off meeting took place for the eCAP project: recipient of a €4.7 million grant from the European Union’s Research and Innovation Programme Horizon Europe. The aim of the project is to deliver a novel medical device combining a smart capsule with an e-health platform to enable better diagnostics, patient empowered disease management and hence, improved outcomes for patients with gastrointestinal (GI) diseases, a major source of population morbidity and care costs worldwide. The consortium, composed of 10 partners from research organisations and industry across Europe and Kenya, will demonstrate the universality of the eCAP solution in clinical trials in France as well as low resource environments by bringing the device to patients who so far have had limited access to GI disease diagnostics.

GI diseases, which range from functional problems to cancers, are among the most common medical ailments across the globe. Gastroesophageal reflux disease (GERD) alone affects an estimated 1.2 billion people globally, with prevalence growing in all regions of the world. Many GI diseases are difficult to diagnose as the symptoms are often vague and variable. Moreover, currently available diagnostics requires highly skilled interpretation and high set-up cost, leading to a dramatic lack of access. For instance, GERD is subject to definitive diagnostic testing in less than 2% of cases.

eCAP enabled diagnostics of GI disease

eCAP enabled diagnostics of GI disease

The eCAP consortium will develop a smart multi-sensing capsule, implanted by minimally invasive techniques, that enables GI physiology monitoring for a controlled period of time. Using ubiquitous smartphone communication standards and cloud computing, real-time patient experience data will be collected through an interactive user-friendly application. Patient-empowered disease management will be supported by accurate interpretation of the data by physicians, aided by Artificial Intelligence. “More accurate, cost-effective, patient-friendly testing for acid reflux is an increasingly urgent need today that the current solutions out on the market do not meet. I think the exciting thing is that this particular group of partners is uniquely suited to getting together to solve the problem of GI diseases affecting people worldwide”, explains Lee Swanström, Project Coordinator from the IHU Strasbourg. “As we began discussions, we had great ideas for expanding the initial proof of concept, even beyond GERD testing, so the project has enormous potential. We certainly thank the European community for recognizing our vision and supporting this project.”

eCAP will run for four years and draw on world-class expertise. The project is led by the Institute of Image-Guided Surgery of Strasbourg (FR). Technical solutions will be developed by Tyndall National Institute (IE), Sentron Europe BV (NL), Integer (IE) and Enterasense (IE), based on the user design input from Imagination Factory (UK). Clinical studies in Kenya and Ukraine will be conducted by Operating Theatre Practitioners Association of Kenya (OTPAK, KE) and a gastroenterology and endoscopy clinic in Kyiv – Olymed (UA), which continues to be actively involved in the project, despite the devastating hurdles they are undergoing today. Health economic analysis will be undertaken by Betthera (CZ) and project management and dissemination activities by AMIRES, The Business Innovation Management Institute (CZ).

Project consortium:


Project duration: 1 May 2022 – 30 April 2026

Press contacts: 

– Lee Swanström (Project Coordinator) lee.swanstrom@localhost

– Kristin Saar (Project Manager)

European Union

Artificial Intelligence enters the operating room: A world first at the IHU Strasbourg

Artificial Intelligence enters the operating room: A world first at the IHU Strasbourg

The scientific and medical teams at the IHU have just taken a major step in the international race towards the surgery of the future. They have successfully deployed an image analysis system driven in real time by computer software using Artificial Intelligence, to automatically control the progress of a minimally invasive operation on a patient.


During the operation performed by Prof. Didier Mutter on 25th November, a minimally invasive gallbladder removal, the video acquired by the endoscopic camera was analyzed in real time by Artificial Intelligence algorithms designed Prof. Nicolas Padoy and his team at IHU/University of Strasbourg. The software can follow all stages of the operation and movement of the instruments, recognize the anatomy, and automatically perform controls of the surgical scene at key steps. All the information can be communicated to the surgical team in the form of notifications or augmented reality images that are completely synchronous with the video of the operating field. The operation was broadcast live from one of the Strasbourg IHU operating rooms on the screens of the Digestive Surgery Congress in Rome and the World Congress of Endoscopic Surgery in Barcelona.

Good Laboratory Practice (GLP) compliance obtained by IHU Strasbourg

Good Laboratory Practice (GLP) compliance obtained by IHU Strasbourg

The University Hospital Institute (IHU) of Strasbourg has become the first French facility to obtain recognition of compliance with good laboratory practice for the preclinical evaluation of medical devices.

Operating room of the experimental platform at the IHU Strasbourg

Operating room of the experimental platform at the IHU Strasbourg © IHU Strasbourg

Recognition by the ANSM

On October 21, following over two years of work, the French National Agency for the Safety of Medicines and Health Products (ANSM) awarded the Image-Guided Surgery Institute of Strasbourg recognition of compliance with Good Laboratory Practices. This recognition concerns implantable medical devices (vascular or digestive stents, surgical clips, prostheses) and diagnostic or treatment assistance devices, both hardware and software, including systems based on Artificial Intelligence.

The IHU in Strasbourg is the first academic institute in France, and one of the very first in Europe to obtain this recognition.

A guarantee for Industry

Certification of GLP compliance sets the IHU of Strasbourg apart from its peers for industry partners and collaborators. It allows them to simplify and accelerate their own accreditation processes, but also to test products before they are approved. Valid on the European market (CE marking), but also in all OECD member countries including the USA (FDA) and Japan, the accreditation represents the Industry’s confidence in trusting the IHU’s preclinical expertise.

An experimental platform and network of experts that are unique in the world

Une plateforme expérimentale et un réseau d’experts unique au monde

The IHU’s experimental platform is fitted with cutting-edge equipment in the fields of surgery, imaging, and minimally invasive therapies (flexible endoscopy, endovascular or percutaneous treatments, robot-assisted surgery). Since its creation, over fifty industry or academic laboratory professionals have been able to work in this platform in a wide range of fields, from hepato-gastroenterology, to cardiovascular studies, neurology and neurosurgery, as well as urology, interventional pneumology, thoracic surgery, gynaecology, and orthopaedics. By coming to the IHU in Strasbourg, manufacturers benefit from the expertise and tailor-made services of an internationally recognized research institute to test and verify the safety and expected effectiveness of their medical devices.

According to IHU Director, Benoît Gallix, “The recognition of GLP compliance should enable us to double this contracted research for industry professionals within two years”.

Customized services to meet the needs of the market

We provide tailor-made services to meet the needs of our customers. We accompany them from the preparation of their research plan by advising them on the experiments most suited to meeting their objectives and go as far as providing them with a complete report that can include a file for submissions to regulatory authorities.

Our experts are personally involved in these studies so as to contribute their knowledge and expertise and may also participate in the improvement of the product or the procedure thanks to their experience feedback.

The services we offer also apply to the organization of training sessions with industrial customers to train practitioners in the use of a new medical device or a new therapeutic approach. More particularly, we have a catalogue of preclinical in vivo and ex vivo models that we can adapt to the needs of our customers (catalogue provided on request) for a tailor-made course, adapted to the specificities of the device.

Télécharger la brochure de la plateforme expérimentale (en anglais)Download the brochure of the experimental platform

Read the press release – 08/11/2021 by Noiizy

COVID-19 Related olfactory disorders: 96% Recovery at 1 year

COVID-19 Related olfactory disorders: 96% Recovery at 1 year

In an article published in the medical journal JAMA Network Open, the ENT team of the University Hospitals of Strasbourg (Dr. Marion Renaud), with the support of the IHU Strasbourg, is the first to describe the one-year prognosis of post-COVID-19–related anosmia. Their results are reassuring!  A large majority (85%) of patients regained a fairly normal sense of smell within the first 6 months and 96% of patients had completely recovered their sense of smell within a year!

Clinical Outcomes for Patients With Anosmia 1 Year After COVID-19 Diagnosis

Crédit photo :


Read the full article at JAMA Network Open

The article was read more than 10,000 times in 72 hours and received great news coverage both nationally and internationally, with more than 100 press articles, including:

HUS Strasbourg